Institutional members access full text with Ovid®

Share this article on:


King, Jennifer R. PharmD*; Acosta, Edward P. PharmD*; Yogev, Ram MD†; Wiznia, Andrew MD‡; Kraimer, Joyce MS§; Graham, Bobbie MS¶; Carey, Vincent PhD∥; Britto, Paula MS∥; Jean-Philippe, Patrick MD**; Moye, John MD††; Watson, Douglas MD‡‡

Pediatric Infectious Disease Journal: February 2009 - Volume 28 - Issue 2 - pp 159-161
doi: 10.1097/INF.0b013e3181861d8b
Brief Reports

The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m2 twice daily and efavirenz (EFV) 350 mg/m2 once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m2 may not be sufficient.

From the *The University of Alabama at Birmingham, Birmingham, AL; †Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL; ‡Jacobi Medical Center, Brooklyn, NY; §Social and Scientific Systems Inc, Silver Spring, MD; ¶Frontier Science and Technology Research Foundation, Buffalo, NY; ∥Harvard School of Public Health, Boston, MA; **Henry Jackson Foundation, Therapeutic Research Program, DAIDS/NIAID/NIH, Bethesda, MD, ††The Pediatric Adolescent and Maternal AIDS Branch, NICHD, Bethesda, MD; and ‡‡University of Maryland, Baltimore, MD.

Accepted for publication July 9, 2008.

Supported by grant number U01AI068632 from the National Institute of Allergy and Infectious Diseases.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

Address for correspondence: Jennifer R. King, PharmD, Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, VH 101A, Birmingham, Alabama 35294-0019. E-mail:

© 2009 Lippincott Williams & Wilkins, Inc.